Document is current

Article History

Received: 18 July 2023

Revised: 22 November 2023

Accepted: 27 November 2023

First Online: 9 January 2024

Declarations

:

: D. Maruyama has received research funding from Celgene, Novartis, Chugai, Ono Pharmaceutical, Takeda, Janssen, MSD, Bristol Myers Squibb, Sanofi, GSK, HUYA, Loxo Oncology, MEI Pharma, AstraZeneca, AbbVie, Symbio, Bayer, Mundipharma, Yakult, Kyowa Kirin, Otsuka, Amgen, Astellas Pharma, Eisai, and Taiho; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen, Mundipharma, Eisai, Chugai, Sanofi, Takeda, Celgene, Bristol Myers Squibb, Ono Pharmaceutical, AbbVie, Novartis, MSD, Kyowa Kirin, Zenyaku, AstraZeneca, Symbio, Meiji Seika Pharma, Nippon Shinyaku, and Eli Lilly. K. Izutsu has received consulting fees from Kyowa Kirin, Eisai, Genmab, AbbVie, Ono Pharmaceutical, and Daiichi Sankyo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Eisai, Chugai, Janssen, AstraZeneca, Novartis, Bristol Myers Squibb, Celgene, Kyowa Kirin, AbbVie, Ono Pharmaceutical, Eli Lilly, MSD, Daiichi Sankyo, Kyorin Pharmaceutical, Symbio, Takeda, Allergan Japan, and FIJIFILM Toyama Chemical; and has received payment for participating on an advisory board for Takeda, Celgene, Genmab, AstraZeneca, AbbVie, and Janssen. A. Omi, F. Nomura, T. Touma, Y. Noguchi, and K. Takebe are full time employees of Janssen Pharmaceutical K.K.

: This surveillance was conducted in compliance with Japanese Good Post-Marketing Study Practice regulations. The protocol was reviewed and approved by the Pharmaceuticals and Medical Devices Agency of Japan.

: As this was a mandatory PMS assessing the use of ibrutinib in an approved indication and anonymized data were collected from clinical settings, informed consent from the patients was not required for the collection and use of their data.